Best treatments for hepatocellular carcinoma
8 products may treat hepatocellular carcinoma, spanning FDA drug classes such as kinase inhibitor. The current highest-rated option is tecentriq. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 8 drugs we list for hepatocellular carcinoma, none are yet flagged as generics in our price data, spanning classes such as kinase inhibitor. 1 of 8 carry a safety score of 72 out of 100. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for hepatocellular carcinoma — so confirm the right choice with your prescriber.
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | — | No data | — | View → | |
| 3 | Not yet rated | Prescription | Tablet | Kinase Inhibitor | No data | — | View → | |
| 4 | Not yet rated | Prescription | Injectable | — | No data | — | View → | |
| 5 | Not yet rated | Prescription | Injectable | — | No data | — | View → | |
| 6 | Not yet rated | Prescription | Tablet | Kinase Inhibitor | No data | — | View → | |
| 7 | Not yet rated | Prescription | Tablet | — | No data | — | View → | |
| 8 | Not yet rated | Prescription | Injectable | — | No data | — | View → |
Narrow by drug class
Explore the class hubs: kinase inhibitor
Full ranking · 8 treatments
tecentriq
PrescriptionFDA-sourced
Tecentriq (Atezolizumab) is a medication used to treat Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma, Melanoma.
Price varies
imjudo
PrescriptionFDA-sourced
Imjudo (Tremelimumab-Actl) is a medication used to treat Hepatocellular Carcinoma.
Price varies
nexavar
PrescriptionFDA-sourced
Nexavar (Sorafenib Tosylate) is a kinase inhibitor used to treat Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms.
Price varies
pegasys
Boxed warningPrescriptionFDA-sourced
Pegasys (Peginterferon Alfa-2a) is a medication used to treat Brain Neoplasms, Renal Cell Carcinoma, Cryoglobulinemia, Hepatitis D.
Price varies
pegintron
PrescriptionFDA-sourced
Pegintron (Peginterferon Alfa-2b) is a medication used to treat Brain Neoplasms, Renal Cell Carcinoma, Cryoglobulinemia, Hepatitis D.
Price varies
sorafenib tosylate
PrescriptionFDA-sourced
Sorafenib Tosylate is a kinase inhibitor used to treat Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms.
Price varies
Frequently asked
- What treats hepatocellular carcinoma?
- Our catalog lists 8 products that may treat hepatocellular carcinoma, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is tecentriq.
- What is the best-rated treatment for hepatocellular carcinoma?
- By our independent recall-safety rating — not an efficacy measure — tecentriq ranks highest among the products we list for hepatocellular carcinoma. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat hepatocellular carcinoma?
- Treatments for hepatocellular carcinoma span FDA drug classes including kinase inhibitor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Where this ranking comes from
Our score is computed from public FDA data — not from opinion, sponsorship or user votes. How we rate.
- FDA Drug Enforcement (recall) database — the recall history behind the safety score
- DailyMed (NIH National Library of Medicine) — the FDA labels we quote for uses, dosing and warnings
- Drugs@FDA — approvals, strengths and marketing status